A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.
Researchers from the University of Southern California found a genetic variant contributing to disparities in childhood leukemia risk. The variant, located on the IKZF1 gene, helps explain why Hispanic/Latino children face a higher risk of acute lymphoblastic leukemia and offers insights about what causes the disease.
Jasper Health, a virtual cancer care navigation and supportive care solution, is collaborating with The Leukemia & Lymphoma Society to provide comprehensive support and resources to blood cancer patients and their caregivers.
David Swoboda was named clinical director of leukemia at Tampa General Hospital Cancer Institute.
Now that the Medicare re-enrollment period has arrived (Oct. 15-Dec. 7), senior Americans are exposed to ubiquitous advertisements, phone calls, and other mechanisms to convince them to enroll in Medicare Advantage rather than traditional Medicare plans.
Research from City of Hope and the Translational Genomics Research Institute, part of City of Hope, suggests that loss of a specific RNA molecule, miR-142, may lead to more aggressive forms of chronic myeloid leukemia.
Sara Small was named assistant professor in the Department of Bone Marrow Transplant and Cellular Therapies at Fox Chase Cancer Center.
Hagop Kantarjian will be awarded the American Society of Clinical Oncology’s 2023 David A. Karnofsky Memorial Award for his contributions to leukemia clinical research and his dedication to improving the lives of patients.
In a study published in Blood, scientists from the USC Stem Cell laboratory of Rong Lu discovered a mechanism that linked a leukemic mutation to varying potentials for disease development—a discovery which could eventually lead to a way to identify patients with the mutation who are most at risk.
A clinical study testing revumenib, a novel targeted treatment, found 40% of patients with acute leukemia had complete response and showed how the cancer cells resist the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
